

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

## Ombitasvir+paritaprevir+ritonavir + dasabuvir Agents

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Based on Genotype, Treatment status, or Cirrhosis status

Medication	Quantity Limit
Viekira Pak (ombitasvir + paritaprevir + ritonavir + dasabuvir)	4 tablets per day

### APPROVAL DURATION

Genotype and Status (HCV mono-infected or HCV/HIV-1 co-infected <sup>a</sup> )	Associated Treatment Regimens	Total Approval Duration of ombitasvir + paritaprevir + ritonavir + dasabuvir agents (Viekira Pak)
Genotype 1b (treatment naïve or dual P/R <sup>2b</sup> treatment-experienced, with compensated cirrhosis or without cirrhosis)	Viekira Pak	12 weeks
Genotype 1a, unknown Genotype 1 subtype, or mixed Genotype 1 subtypes (treatment naïve or dual P/R <sup>2b</sup> treatment-experienced, without cirrhosis)	Viekira Pak+ RBV	12 weeks
Genotype 1a, unknown Genotype 1 subtype, or mixed Genotype 1 subtypes (treatment-naïve or dual P/R <sup>2b</sup> treatment-experienced, with compensated cirrhosis)	Viekira Pak+ RBV	24 weeks <sup>b</sup>

### APPROVAL CRITERIA

Requests for ombitasvir + paritaprevir + ritonavir + dasabuvir (Viekira Pak) may be approved if the following criteria are met:

CRX-ALL-0565-20

PAGE 1 of 5 07/01/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

- I. Individual is 18 years of age or older; **AND**
- II. Documentation is provided for a diagnosis of chronic hepatitis C (CHC) infection<sup>a</sup>, which includes genotype and a positive HCV RNA result (AASLD/IDSA 2017, CDC 2013); **AND**
- III. Individual has received baseline evaluation for liver fibrosis to guide appropriate therapy; **AND**

- IV. Individual does not have a short life expectancy (less than 12 months owing to non-liver related comorbid conditions) that cannot be remediated by treating HCV, by transplantation or other directed therapy (AASLD/IDSA 2017); **AND**
- V. Individual has Genotype 1 and compensated liver disease<sup>1</sup> (with or without cirrhosis);

**AND**

- VI. Individual has had a prior trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response to authorized generic Epclusa (sofosbuvir/velpatasvir) OR Mavyret, unless the one of following conditions apply:

- A. Individual is using with **one** of the following antiviral treatment regimens (Label):

- 1. As monotherapy for individuals with Genotype 1b, treatment-naïve or dual P/R<sup>2b</sup> treatment-experienced, with compensated<sup>1</sup> cirrhosis or without cirrhosis; **AND**

- a. Individual meets one of the following criteria:

- i. Prior trial of authorized generic Epclusa (sofosbuvir/velpatasvir) AND Mavyret with documented hypersensitivity, as manifested by a severe allergic reaction to any ingredient which is not also in Viekira Pak; **OR**
- ii. Individual is currently on and completing a course of therapy with the requested regimen; **OR**
- iii. Individual is concurrently using an agent that cannot be substituted with another agent or temporarily discontinued and is contraindicated or not recommended for concomitant use with the preferred regimen or regimens;

**OR**

- 2. In combination with ribavirin for the following:

- a. Individual with Genotype 1a or mixed/unknown Genotype1, treatment-naïve or dual P/R<sup>2b</sup> treatment-experienced, with compensated cirrhosis<sup>1</sup> without cirrhosis; **AND**

- b. Individual meets one of the following criteria:

- i. Prior trial of authorized generic Epclusa (sofosbuvir/velpatasvir) AND Mavyret with documented hypersensitivity, as manifested by a severe allergic reaction to any ingredient which is not also in Viekira Pak; **OR**
- ii. Individual is currently on and completing a course of therapy with the requested regimen; **OR**
- iii. Individual is concurrently using an agent that cannot be substituted with another agent or temporarily discontinued and is contraindicated or not

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

recommended for concomitant use with the preferred regimen or regimens.

Ombitasvir + paritaprevir + ritonavir + dasabuvir (Viekira Pak) may **not** be approved for the following:

- I. Individual has decompensated<sup>1</sup> cirrhosis; **OR**
- II. Individual is requesting in concurrent therapy with contraindicated or not recommended agents, including but not limited to the following: Strong cytochrome (CYP) 2C8 inhibitors [including but not limited to, gemfibrozil, ritonavir-boosted atazanavir], strong CYP 2C8 inducers (including but not limited to, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, apalutamide), moderate or strong CYP 3A4 inducers (including but not limited to, phenytoin, St. Johns' Wort, efavirenz-based regimens, agents highly dependent on CYP3A clearance (substrates) [including but not limited to, lomitapide, dronedarone, amiodarone, flecainide, propafenone, quinidine, ranolazine, lurasidone, cisapride, alfuzosin, colchicine, ergot derivatives, ethinyl estradiol-containing agents, lovastatin, simvastatin, pimozide, Revatio, triazolam, oral midazolam, darunavir, lopinavir/ritonavir, rilpivirine-based regimens, voriconazole, salmeterol], atorvastatin, everolimus, sirolimus, tacrolimus, tipranavir/ritonavir, etravirine, nevirapine or cobicistat-containing regimens; **OR**
- III. Individual is using in combination with a regimen containing another NS3/4A<sup>2c</sup> protease inhibitor; **OR**
- IV. Individual is using in combination with a regimen containing another nucleotide NS5B polymerase inhibitor (such as sofosbuvir) or another non-nucleoside NS5B polymerase inhibitor (such as dasabuvir); **OR**
- V. Individual is using in combination with a regimen containing another NS5A<sup>2a</sup> inhibitor; **OR**
- VI. Individual is requesting the regimen for re-treatment and either failed to achieve a SVR (defined as a lower limit HCV RNA of 25 IU/mL) or relapsed after achieving a SVR during a prior successfully completed treatment regimen consisting of a NS3/4A<sup>2c</sup> protease inhibitor, NS5A<sup>2a</sup> inhibitor, or NS5B polymerase inhibitor (such as sofosbuvir or dasabuvir).

**Notes:**

<sup>a</sup>Per label and AASLD/IDSA treatment guidance, ombitasvir/paritaprevir/ritonavir + dasabuvir agents (Viekira Pak) may be used in individuals co-infected with HIV-1. Individuals co-infected with HCV/HIV-1 treated with Viekira Pak should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance.

<sup>b</sup>Per label, ombitasvir + paritaprevir + ritonavir + dasabuvir agents (Viekira Pak) plus ribavirin for 12 weeks may be considered in certain patients based on prior treatment history, such as those who are treatment-naïve.

**1. Compensated Liver Disease:**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

According to the American Association for the Study of Liver Diseases (AASLD/IDSA2017), the specific criteria for compensated liver disease include all of the following: a total bilirubin; serum albumin; prothrombin time/INR; presence of ascites; and presence of hepatic encephalopathy. However, these criteria do not establish a comprehensive definition of compensated liver disease. The AASLD guidance refers to compensated liver disease as Class A based on the Child Pugh-Turcotte (CPT) classification scoring system.

Moderate to Severe (Decompensated) Liver Disease:

The AASLD guidance refers to decompensated (moderate to severe) liver disease as Class B or C based on the Child-Pugh Turcotte (CPT) classification scoring system.

### Child Pugh Classification (AASLD/IDSA 2017)

Parameters			
Points Assigned	1 point	2 points	3 points
Total Bilirubin (µmol/L)	<34	34-50	>50
Serum Albumin (g/L)	>35	28-35	<28
Prothrombin time/INR	<1.7	1.71-2.30	>2.30
Ascites	None	Mild	Moderate to Severe
Hepatic Encephalopathy	None	Grade I-II (or suppressed with medication)	Grade III-IV (or refractory)

### Child Pugh Score Interpretation (AASLD/IDSA 2017)

Class A	5-6 points	Well compensated liver disease
Class B	7-9 points	Significant functional compromise (moderate hepatic impairment)
Class C	10-15 points	Uncompensated liver disease (severe hepatic impairment)

## 2. Past Treatment Exposure Definitions (AASLD/IDSA 2017):

- a. NS5A Inhibitor: includes daclatasvir, ledipasvir, elbasvir, ombitasvir, pibrentasvir, or velpatasvir-containing regimens
  - b. P/R: includes peginterferon (or non-pegylated interferon) ± ribavirin
  - c. NS3/4A Protease Inhibitor: includes simeprevir, grazoprevir, paritaprevir, glecaprevir, and voxilaprevir-containing regimens
  - d. Triple therapy: includes NS3 protease inhibitor (simeprevir, boceprevir or telaprevir) plus peginterferon and ribavirin
  - e. Direct Acting Antiviral (DAA): includes NS5A inhibitors, NS3/4A protease inhibitors, and NS5B polymerase inhibitors (sofosbuvir, dasabuvir)
- c. Chronic Kidney Disease (CKD) Definitions (AASLD/IDSA 2017):  
 Severe CKD (Stage 4): eGFR 15-29 mL/min  
 End-Stage CKD (Stage 5): eGFR < 15 mL/min

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	NA	NA	X	NA	X	X	NA

d. **Metavir Scoring Systems for Fibrosis Staging (AASLD 2009):**

Stage (F)	
0	No fibrosis
1	Periportal fibrotic expansion
2	Periportal septae 1 (septum)
3	Porto-central septae
4	Cirrhosis

- e. Hepatitis C virus (HCV) direct acting antiviral (DAA) agents have a black box warning for risk of hepatitis B virus (HBV) reactivation in individuals with HCV-HBV co-infection. Individuals should be tested for evidence of current or prior HBV infection prior to initiation of DAA therapy. HBV reactivation has been reported in HCV/HBV co-infected individuals currently taking or previously completed DAA therapy and not concomitantly receiving HBV antiviral therapy. Some cases of HBV reactivation have led to fulminant hepatitis, hepatic failure, and death. Individuals should be monitored for hepatitis flare or HBV reactivation during and following HCV DAA therapy. Individuals should be appropriately managed for HBV infection as indicated.

**Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2020. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 13, 2020.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. American Association for the Study of Liver Diseases and the Infectious Disease Society of America, in collaboration with the International Antiviral Society-USA. Recommendations for testing, managing and treating hepatitis C. Available at <http://www.hcvguidelines.org/>. Published on: January 29, 2014. Updated on: November 6, 2019. Accessed on: January 13, 2020
6. Centers for Disease Control and Prevention. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. *MMWR*. 2013; 62(18):362-365. Available from: <https://www.cdc.gov/mmwr/pdf/wk/mm6218.pdf>. Accessed on: January 13, 2020.
7. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol*. 2018; <https://doi.org/10.1016/j.jhep.2018.03.026>. Available from: <http://www.easl.eu/research/our-contributions/clinical-practiceguidelines/detail/easl-recommendations-on-treatment-of-hepatitis-c-2018>. Accessed on: January 13, 2020.
8. Kamal SM. Acute hepatitis C: a systematic review. *Am J Gastroenterol*. 2008;103(5):1283-1297.
9. U.S. Department of Health and Human Services AIDSinfo treatment guidelines. Considerations for Antiretroviral Use in Patients with Coinfections. Available at <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/26/hcv-hiv>. Accessed on: January 13, 2020.
10. Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. *J Hepatol*. 2019;70(5):1019-1023.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.